Product image of Linagliptin Fmk (Linagliptin) supplied by GNH India

Linagliptin Fmk

Active Ingredient:
Linagliptin
Origin:
EU

Linagliptin Fmk (Linagliptin)

Linagliptin, the active ingredient in Linagliptin Fmk, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a tablet for oral use. It selectively inhibits the DPP‑4 enzyme, increasing incretin levels and improving glycemic control in adults with type 2 diabetes.

GNH India supplies Linagliptin Fmk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, and the product conforms to European Union marketing authorization standards.

Manufacturer / TM Owner

Farmak International Sp. Z O.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptin is a DPP‑4 inhibitor used to manage hyperglycaemia in type 2 diabetes.

  • Type 2 diabetes mellitus (monotherapy): reduces HbA1c as a single oral agent.
  • Type 2 diabetes mellitus (combination therapy): enhances glucose control when added to metformin or other oral antidiabetics.
  • Type 2 diabetes mellitus (adjunct to lifestyle): supports diet and exercise in achieving target blood glucose levels.

How It Works

  • Linagliptin selectively binds to the active site of the dipeptidyl peptidase‑4 enzyme, preventing the degradation of endogenous incretin hormones (GLP‑1 and GIP). This prolongs incretin activity, leading to glucose‑dependent stimulation of insulin secretion, suppression of glucagon release, and ultimately improved post‑prandial and fasting glycaemic control without causing hypoglycaemia when used alone.

Side Effects

Common Side Effects

  • Nasopharyngitis: mild upper respiratory tract infection symptoms.
  • Headache: transient mild to moderate pain.
  • Dizziness: occasional light‑headed sensation.
  • Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea.
  • Back pain: occasional musculoskeletal discomfort.
  • Arthralgia: joint pain without swelling.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.
  • Hepatic injury: elevated liver enzymes or jaundice.
  • Hypoglycaemia (when combined with sulfonylureas or insulin): symptoms of low blood sugar.
  • Bullous pemphigoid: blistering skin disorder.
  • Stevens‑Johnson syndrome: rare severe skin reaction.

Precautions & Warnings

Linagliptin should be used with clinical monitoring in specific patient groups.

  • Renal impairment: assess kidney function; dose adjustment may be required.
  • Hepatic impairment: monitor liver enzymes regularly.
  • Concomitant sulfonylureas or insulin: watch for signs of hypoglycaemia.
  • Pregnancy: safety not established; avoid unless benefits outweigh risks.
  • Elderly patients: increased vigilance for adverse reactions.
  • Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Avoid Interactions

Linagliptin may interact with several medicines that affect its plasma levels or glycaemic response.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure.
  • Strong P‑gp inducers (e.g., rifampin): may reduce efficacy.
  • Sulfonylureas or insulin: heightened risk of hypoglycaemia.

Moderate Interactions (Monitor Closely)

  • ACE inhibitors or ARBs: monitor renal function and potassium.
  • Diuretics: watch for electrolyte disturbances.
  • Warfarin: periodic INR checks are advisable.

Frequently Asked Questions

Linagliptin Fmk contains the active ingredient linagliptin, a DPP‑4 inhibitor indicated for improving glycaemic control in adults with type 2 diabetes mellitus, typically as part of a comprehensive treatment plan that includes diet and exercise.

Linagliptin selectively inhibits the dipeptidyl peptidase‑4 enzyme, which prevents the breakdown of incretin hormones such as GLP‑1 and GIP. This prolongs their action, leading to glucose‑dependent insulin release, reduced glucagon secretion, and lower blood glucose levels.

The appropriate dose of Linagliptin Fmk is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal and hepatic function, and concomitant therapies. Patients should follow the prescriber’s instructions exactly.

Safety of linagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by the treating physician.

To place an order, submit an enquiry on the Linagliptin Fmk product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas, linagliptin has a lower risk of hypoglycaemia when used alone and does not cause weight gain. Unlike metformin, it is not contraindicated in moderate renal impairment, making it a useful alternative for patients with reduced kidney function.

Linagliptin Fmk tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children.

Linagliptin Fmk is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless otherwise directed by a healthcare professional.

Serious risks include pancreatitis, severe allergic reactions such as anaphylaxis, and rare skin disorders like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or any signs of an allergic reaction.

Linagliptin Fmk is contraindicated in patients with a known hypersensitivity to linagliptin or any of the tablet’s excipients. Caution is advised for individuals with severe renal or hepatic impairment, and it should be avoided in pregnancy unless clearly indicated by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT